Benjamin J. Zeskind - 18 Jun 2025 Form 4 Insider Report for Immuneering Corp (IMRX)

Role
PRESIDENT AND CEO, Director, 10%+ Owner
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Issuer symbol
IMRX
Transactions as of
18 Jun 2025
Net transactions value
+$50,144
Form type
4
Filing time
20 Jun 2025, 09:09:33 UTC
Previous filing
07 Feb 2025
Next filing
03 Jul 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Zeskind Benjamin J. PRESIDENT AND CEO, Director, 10%+ Owner 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind 20 Jun 2025 0001870062

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMRX Class A Common Stock Purchase $50,144 +21,000 +0.92% $2.39 2,302,852 18 Jun 2025 Direct F1
holding IMRX Class A Common Stock 894,927 18 Jun 2025 See Foonote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed in multiple trades through a broker-dealer at prices ranging from $2.31 to $2.44. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.
F2 Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.